CN105326816B - Medicinal eye sticker - Google Patents
Medicinal eye sticker Download PDFInfo
- Publication number
- CN105326816B CN105326816B CN201410387365.4A CN201410387365A CN105326816B CN 105326816 B CN105326816 B CN 105326816B CN 201410387365 A CN201410387365 A CN 201410387365A CN 105326816 B CN105326816 B CN 105326816B
- Authority
- CN
- China
- Prior art keywords
- layer
- thickness
- drug
- polylactic acid
- gelatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A kind of medicinal eye sticker, including the polylactic acid film layer medically approved, medicine layer, gelatin layer, overlay film, the polylactic acid thicknesses of layers accounts for the 1/8-1/6 of drug layer thickness；The medicine layer has honeycomb structure, with a thickness of 50-60 μm；Institute's gelatin layer is with a thickness of the 1/10 of drug layer thickness；The coating layer is the 1/10 of drug layer thickness；The medicine layer is between polylactic acid film layer and gelatin layer；The coating layer is close to gelatin layer, is located at eye sticker outermost layer.The eye sticker is the medicinal eye sticker that one kind can assist in the treatment of diabetic macular edema, solves externally applied drug in the prior art and is difficult to break through blood-retina barrier, it is difficult to which the problem of playing drug effect, structure is simple, and design is scientific and reasonable, and cost is relatively low.
Description
Technical field
The present invention relates to a kind of sugared net patient medical assistant product, in particular to a kind of medicinal eye stickers.
Background technique
Blood-retina barrier (blood-retinalbarrier, BRB) can stop intravascular as blood brain barrier
Blood constituent, macromolecular substances and toxicant leak into retina, to maintain the transparency of optical medium, maintain optimal view
Nethike embrane aquation and retinal thickness maintain the dynamic equilibrium of retinal microenvironment.Therefore, complete BRB is to maintain view
Necessary to the normal structure and function of film.BRB points are interior barrier (inner-blood-retinalbarrier, iBRB) and outer
Barrier (outerblood-retinalbarrier, oBRB).FfiRB is mainly by between retinal capillary endothelial cell
Close connection (tight-junctions, TJs) composition.Pericyte and Deiter's cells play bracket to ffiRB.oBRB
Mainly by the nearly top matter in the side two adjacent retinal pigment epitheliums (retinalpigmentepithelium, RPE)
Film outer plate is in close contact the TJs composition to form, is looped around around each epithelial cell in continuous net-shaped, stops choriocapillary
Blood vessel leaks into retina, plays common protection retinal microenvironment with ffiRB-.Under pathological state (such as hypoxic-ischemic,
Inflammation, blood vessel drawing or metabolic disorder etc.), the TJs between capillary endothelial cell and RPE is opened, barrier breakdown, blood
Ingredient and macromolecular substances leak into retinal tissue gap by lumen of vessels and RPE, form macular edema.Betide macula lutea
The main reason for oedema in area is known as macular edema, and macular edema is visual impairment or even blinds, therefore the treatment of macular edema
It is particularly significant.
In order to overcome blood-paropion barrier, intravitreal method is mostly used, but long-term intravitreal has biggish eye
Endotoxic, drug effect is not lasting enough, while because of intravitreal injection repeatedly, also increasing the risk of intraocular infection and bleeding.In order to tie up
Effective drug concentration is held, domestic and international research tendency is that drug application slow-released system (drugdeliverysystem, DDS) makes medicine
Object slowly or is controlledly discharged in eye, reduces the dosage and number of ophthalmic administration, hence it is evident that improve the bioavilability of drug
And reduce toxicity.The DDS applied at present is broadly divided into implanted device and injection particle.Implanted device can be divided into: (1) abiotic drop
Solve implanted device, (2) biodegrade implanted device: hydrophobicity and hydrophily.Injection particle mainly has: (1) liposome, (2) are micro-
Ball and nanoparticles: hydrophobicity and hydrophily, (3) other: lotion, micella etc..However DDS has the following problems at present: opaque
It affects vision, drug diffusion is uneven, and pharmaceutical dosage form is few, and price is more expensive, seriously limits its popularization.
Laser therapy is also a kind of effective measures of current treatment sugar net at present, but due to its requirement to operation doctor
It is higher, it in addition also to individual patient requirement with higher, or can also cause new new vessels accidentally, lead to patient's state of an illness
Vicious circle, therefore there is also certain drawbacks for the therapeutic modality.
Currently, by improving the structure feature of eye mask, being controlled by being applied with medicine film with the fast development of modern biotechnology material
It treats sugared net and has become a kind of possibility.
Summary of the invention
In view of the deficiencies of the prior art, the present invention provides a kind of medicinal eye that can assist in the treatment of diabetic macular edema
Patch solves externally applied drug in the prior art and is difficult to break through blood-retina barrier, it is difficult to the problem of playing drug effect.The medicinal eye sticker knot
Structure is simple, and design is scientific and reasonable, and cost is relatively low.
The present invention solves its technical problem and is achieved through the following technical solutions:
A kind of medicinal eye sticker is provided, including the polylactic acid film layer medically approved, medicine layer, gelatin layer, overlay film, feature
It is, the polylactic acid thicknesses of layers accounts for the 1/8-1/6 of drug layer thickness；The medicine layer has honeycomb structure, with a thickness of 50-60
μm；Institute's gelatin layer is with a thickness of the 1/10 of drug layer thickness；The coating layer is the 1/10 of drug layer thickness；The medicine layer position
Between polylactic acid film layer and gelatin layer；The coating layer is close to gelatin layer, is located at eye sticker outermost layer.
Moreover, the polylactic acid membrane layer porosity is 40-60%.
Moreover, the honeycomb structure is regular hexagon, round or ellipse.
Moreover, coating layer is adhesive, it is surface through the processed smooth ground paper of paraffin or methyl-silicone oil.
Moreover, the polylactic acid film layer, medicine layer, gelatin layer overlayed with coating layer together with form.
Compared with prior art, polylactic acid film layer of the present invention can be directly attached on periocualr skin, and mild non-stimulated,
Drug granule can pass through the film and penetrate into eyeground, and part polylactic acid molecule can be in conjunction with drug granule, and being formed has slow releasing function
Drug granule enters eye circumference blood circulation, the effect of to reach long-acting treatment eye disease.Medicine layer is tool honeycomb structure, can be straight
It connects and sparges drug granule wherein, above cover gelatin layer, protect the drug from loss, outermost layer is coating layer, protects medicine film, exempts from
It is contaminated, it is easy to carry and use.
Detailed description of the invention
Fig. 1 is a kind of example structure schematic diagram of the medicinal eye sticker of the present invention.
Fig. 2 is that the medicine layer of the medicinal eye sticker of the present invention looks down structural schematic diagram.
Specific embodiment
Presently in connection with attached drawing, the present invention is further illustrated.These attached drawings are simplified schematic diagram only with signal side
Formula illustrates basic structure of the invention, therefore it only shows the composition relevant to the invention, should not be construed as to of the invention real
Apply the limitation of mode.
Embodiment 1
A kind of medicinal eye sticker, including the polylactic acid film layer 4 medically approved, medicine layer 3, gelatin layer 2, overlay film 1, feature
It is, 4 thickness of polylactic acid film layer accounts for the 1/8-1/6 of drug layer thickness；The medicine layer 3 has honeycomb structure, with a thickness of 50-
60μm；Institute's gelatin layer 2 is with a thickness of the 1/10 of drug layer thickness；The coating layer 1 is the 1/10 of drug layer thickness；The drug
Layer 3 is between polylactic acid film layer 4 and gelatin layer 2；The coating layer 1 is close to gelatin layer 2, is located at eye sticker outermost layer.
Moreover, medicinal 4 porosity of eye sticker polylactic acid film layer is 40-60%；3 honeycomb structure of medicine layer is regular hexagon, circle
Shape or ellipse；Coating layer 1 is adhesive, is surface through the processed smooth ground paper of paraffin or methyl-silicone oil.Polylactic acid membrane
Layer 4, medicine layer 3, gelatin layer 2 form together with overlaying with coating layer 1.
Embodiment 2
A kind of medicinal eye sticker, including the polylactic acid film layer 4 medically approved, medicine layer 3, gelatin layer 2, overlay film 1, feature
It is, 4 thickness of polylactic acid film layer accounts for the 1/6 of drug layer thickness；The medicine layer 3 has honeycomb structure, with a thickness of 55 μm；Institute
Gelatin layer 2 is with a thickness of the 1/10 of drug layer thickness；The coating layer 1 is the 1/10 of drug layer thickness；The medicine layer 3 is located at
Between polylactic acid film layer 4 and gelatin layer 2；The coating layer 1 is close to gelatin layer 2, is located at eye sticker outermost layer.
Moreover, medicinal 4 porosity of eye sticker polylactic acid film layer is 45%；3 honeycomb structure of medicine layer be regular hexagon, circle or
Ellipse；Coating layer 1 is adhesive, is surface through the processed smooth ground paper of methyl-silicone oil.Polylactic acid film layer 4, medicine layer
3, gelatin layer 2 overlayed with coating layer 1 together with form.
The drug granule for treating eye disease or gel solution can be sprayed into embodiment 1 and 2 honeycomb drug of embodiment
Layer, then by polylactic acid film layer 4, medicine layer 3, gelatin layer 2, overlay film 1 overlays together, certain shapes is made, is pasted on eye circumference,
This kind of structure drug paste is easy to carry and use, non-stimulated to eye circumference skin, can directly reach lesion, the medicament slow release particle of formation
It is easy to break through blood-retina barrier, is a kind of medical assistance articles of preferable treatment macular edema.
Claims (3)
1. a kind of medicinal eye sticker, including the polylactic acid film layer medically approved, medicine layer, gelatin layer, overlay film, which is characterized in that
The polylactic acid thicknesses of layers accounts for the 1/8-1/6 of drug layer thickness；The medicine layer has honeycomb structure, with a thickness of 50-60 μm；Institute
Gelatin layer is with a thickness of the 1/10 of drug layer thickness；The coating layer is the 1/10 of drug layer thickness；The medicine layer is located at poly-
Between lactic acid film layer and gelatin layer；The coating layer is close to gelatin layer, is located at eye sticker outermost layer, the polylactic acid membrane layer porosity
For 40-60%, the honeycomb structure is regular hexagon, round or ellipse.
2. medicinal eye sticker according to claim 1, which is characterized in that the coating layer is adhesive, is surface through stone
Wax or the processed smooth ground paper of methyl-silicone oil.
3. medicinal eye sticker according to claim 1, which is characterized in that the polylactic acid film layer, medicine layer, gelatin layer and
Coating layer overlays to be formed together.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410387365.4A CN105326816B (en) | 2014-08-07 | 2014-08-07 | Medicinal eye sticker |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410387365.4A CN105326816B (en) | 2014-08-07 | 2014-08-07 | Medicinal eye sticker |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105326816A CN105326816A (en) | 2016-02-17 |
| CN105326816B true CN105326816B (en) | 2019-04-09 |
Family
ID=55277724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410387365.4A Expired - Fee Related CN105326816B (en) | 2014-08-07 | 2014-08-07 | Medicinal eye sticker |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105326816B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103893157A (en) * | 2014-04-09 | 2014-07-02 | 山东赛克赛斯药业科技有限公司 | Hydrogel eye protective pad dressing and preparation method thereof |
| CN203710395U (en) * | 2013-11-05 | 2014-07-16 | 威海金琳水产有限公司 | Fucosan sulphate eye mask |
| CN203970951U (en) * | 2014-08-07 | 2014-12-03 | 天津法莫西医药科技有限公司 | Medicinal eye sticker |
-
2014
- 2014-08-07 CN CN201410387365.4A patent/CN105326816B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN203710395U (en) * | 2013-11-05 | 2014-07-16 | 威海金琳水产有限公司 | Fucosan sulphate eye mask |
| CN103893157A (en) * | 2014-04-09 | 2014-07-02 | 山东赛克赛斯药业科技有限公司 | Hydrogel eye protective pad dressing and preparation method thereof |
| CN203970951U (en) * | 2014-08-07 | 2014-12-03 | 天津法莫西医药科技有限公司 | Medicinal eye sticker |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105326816A (en) | 2016-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kar et al. | Wearable and implantable devices for drug delivery: Applications and challenges | |
| CN104755128B (en) | Retinoic acid micropin | |
| US20180326061A1 (en) | Modified transdermal delivery device or patch and method of delivering insulin from said modified transdermal delivery device | |
| US20080009471A1 (en) | Ocular delivery of triamcinolone acetonide phosphate and related compounds | |
| CN105596287A (en) | Active separation-type soluble microneedle and preparation method thereof | |
| KR20180031679A (en) | Use of mussel adhesive protein products in the treatment and prevention of diseases associated with melanin | |
| CN107213290A (en) | The antibacterial cream of nasal cavity | |
| Dreixler et al. | Delayed post-ischemic conditioning significantly improves the outcome after retinal ischemia | |
| CN105326816B (en) | Medicinal eye sticker | |
| Chandani et al. | A comprehensive review of pulsatile drug delivery system | |
| CN203970951U (en) | Medicinal eye sticker | |
| HRP20200897T1 (en) | Parenteral esmolol formulation | |
| RU2577449C1 (en) | Method of simulating transient retinal ischemia in rats | |
| Taufikurohmah et al. | Utilization Of Nanogold And Nanosilver To Treat Herpes Disease: Case Study Of Herpes Transmission In Islamic Cottage Schools | |
| Bhardwaj et al. | Advanced Drug Delivery System for Management of Chronic Diabetes Wound Healing | |
| CN107530380A (en) | For treating the Taiwan propolis extract of eye illness | |
| An et al. | Novel Microneedle Platforms for the Treatment of Wounds by Drug Delivery: A Review | |
| CN104523656A (en) | Rivastigmine sustained-release transdermal patch and preparation method thereof | |
| Chen et al. | A self-powered controllable microneedle drug delivery system for rapid blood pressure reduction | |
| CN104667262B (en) | BFGF bovine basic fibroblast growth factor externally used solution | |
| CN102504303A (en) | Medical polyurethane film and preparation method thereof | |
| CN104707210B (en) | A kind of feature pad pasting for fixing retention needles and retention tubes | |
| CN202637675U (en) | Integral indwelling needle/indwelling tube functional patch | |
| CN105726698B (en) | Rose composition and eye mask for relieving visual fatigue and preparation method thereof | |
| Ertas et al. | Diagnostic, Therapeutic, and Theranostic Multifunctional Microneedles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190228 Address after: 100176 No. 36 Jinghai Second Road, Daxing Economic and Technological Development Zone, Beijing Applicant after: STAIDSON(BEIJING) BIOPHARMACEUTICALS Co.,Ltd. Address before: 300384 Xinyuan Village, Liqizhuang Street, Xiqing District, Tianjin Applicant before: TIANJIN PHARMACN MEDICAL TECHNOLOGY Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190409 Termination date: 20210807 |